The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity.
Small- and mid-cap life sciences companies typically...more
7/28/2023
/ Capital Raising ,
Convertible Notes ,
Corporate Financing ,
EU ,
Financing ,
Investors ,
Life Sciences ,
PIPEs ,
Private Investment Funds ,
Small and Medium-Sized Enterprises (SMEs) ,
Strategic Planning
The revised provisions provide medical device and in-vitro diagnostics manufacturers with additional time to bring their product into compliance with the new EU Regulations, subject to a number of conditions.
On March 20,...more
The eleventh edition of The Life Sciences Law Review covers a total of 24 jurisdictions, providing an overview of legal requirements of interest to pharmaceutical, biotechnology and medical device companies. The chapters are...more
The regulation aims to harmonise clinical and scientific aspects of HTA to make innovative health technologies more widely available in the EU.
Health technology assessment (HTA) is a multidisciplinary evidence-based...more
France is generally known for its high quality and also highly regulated healthcare system. As an EU Member State, France has implemented the EU medicines and medical devices regimes. This chapter should therefore be read in...more